5-溴-2,3-二羟基吡啶 | 34206-49-0

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-溴-2,3-二羟基吡啶
• 中文别名: 5-溴-2,3-羟基吡啶；5-溴-2,3-吡啶二醇
• 英文名称: 5-bromopyridine-2,3-diol
• 英文别名: 5-bromo-2,3-dihydroxy-pyridine；5-Brom-2,3-dihydroxy-pyridin；5-bromopyridin-2,3-diol；2,3-dihydroxy-5-bromopyridine；5-bromo-3-hydroxy-1H-pyridin-2-one
• CAS: 34206-49-0
• 化学式: C₅H₄BrNO₂
• 分子量: 189.996
• InChiKey: KXBXUHWCODHRHK-UHFFFAOYSA-N

物化性质

• 熔点：
  249 °C
• 沸点：
  309.5±42.0 °C(Predicted)
• 密度：
  2.044

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335

SDS

5-Bromo-2,3-pyridinediol Revision number: 1
SAFETY DATA SHEET

---

Section 1. BASE INFORMATION
Product name: 5-Bromo-2,3-pyridinediol

Revision number: 1

---

Section 2. HAZARDS IDENTIFICATION
Classification of the GHS
PHYSICAL HAZARDS Not classified
HEALTH HAZARDS Not classified
Not classified
ENVIRONMENTAL HAZARDS
GHS label elements
None
Pictograms or hazard symbols
Signal word No signal word
None
Hazard statement
Precautionary statements None

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substance/mixture: Substance
Component(s): 5-Bromo-2,3-pyridinediol
Percent: >98.0%(GC)(T)
CAS Number: 34206-49-0
Synonyms: 5-Bromo-2,3-dihydroxypyridine
Chemical Formula: C5H4BrNO2

---

Section 4. FIRST AID MEASURES
Inhalation: Remove victim to fresh air and keep at rest in a position comfortable for breathing.
Get medical advice/attention if you feel unwell.
Skin contact: Remove/Take off immediately all contaminated clothing. Rinse skin with
water/shower. If skin irritation or rash occurs: Get medical advice/attention.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses, if present
and easy to do. Continue rinsing. If eye irritation persists: Get medical
advice/attention.
Ingestion: Get medical advice/attention if you feel unwell. Rinse mouth.
A rescuer should wear personal protective equipment, such as rubber gloves and air-
Protection of first-aiders:
tight goggles.

---

Section 5. FIRE-FIGHTING MEASURES
Suitable extinguishing Dry chemical, foam, water spray, carbon dioxide.
media:
Specific hazards: Take care as it may decompose upon combustion or in high temperatures to
generate poisonous fume.
5-Bromo-2,3-pyridinediol

---

Section 5. FIRE-FIGHTING MEASURES
Specific methods: Fire-extinguishing work is done from the windward and the suitable fire-extinguishing
method according to the surrounding situation is used. Uninvolved persons should
evacuate to a safe place. In case of fire in the surroundings: Remove movable
containers if safe to do so.
Special protective When extinguishing fire, be sure to wear personal protective equipment.
equipment for firefighters:

---

Section 6. ACCIDENTAL RELEASE MEASURES
Use personal protective equipment. Keep people away from and upwind of spill/leak.
Personal precautions,
protective equipment and Entry to non-involved personnel should be controlled around the leakage area by
emergency procedures: roping off, etc.
Environmental precautions: Prevent product from entering drains.
Methods and materials for Sweep dust to collect it into an airtight container, taking care not to disperse it.
containment and cleaning Adhered or collected material should be promptly disposed of, in accordance with
up: appropriate laws and regulations.

---

Section 7. HANDLING AND STORAGE
Handling
Handling is performed in a well ventilated place. Wear suitable protective equipment.
Technical measures:
Prevent dispersion of dust. Wash hands and face thoroughly after handling.
Use a local exhaust if dust or aerosol will be generated.
Advice on safe handling: Avoid contact with skin, eyes and clothing.
Storage
Storage conditions: Keep container tightly closed. Store in a cool and dark place.
Store away from incompatible materials such as oxidizing agents.
Packaging material: Law is followed.

---

Section 8. EXPOSURE CONTROLS / PERSONAL PROTECTION
Engineering controls: Install a closed system or local exhaust as possible so that workers should not be
exposed directly. Also install safety shower and eye bath.
Personal protective equipment
Respiratory protection: Dust respirator. Follow local and national regulations.
Hand protection: Protective gloves.
Eye protection: Safety glasses. A face-shield, if the situation requires.
Skin and body protection: Protective clothing. Protective boots, if the situation requires.

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Physical state (20°C): Solid
Form: crystal - powder
Color: Very pale yellow - Yellow
Odor: No data available
pH: No data available
Melting point/freezing point:249 °C
Boiling Point/Range: No data available
Flash Point: No data available
Explosive limits
Lower: No data available
Upper: No data available
Density: No data available
Solubility: No data available

---

Section 10. STABILITY AND REACTIVITY
Stability: Stable under proper conditions.
Reactivity: No special reactivity has been reported.
Incompartible materials: oxidizing agents
5-Bromo-2,3-pyridinediol

---

Section 10. STABILITY AND REACTIVITY
Hazardous Decomposition Carbon monoxide, Carbon dioxide, Nitrogen oxides (NOx), Hydrogen bromide
Products:

---

Section 11. TOXICOLOGICAL INFORMATION
Acute Toxicity: No data available
Skin corrosion/irritation: No data available
Serious eye No data available
damage/irritation:
Germ cell mutagenicity: No data available
Carcinogenicity:
IARC = No data available
NTP = No data available
Reproductive toxicity: No data available

---

Section 12. ECOLOGICAL INFORMATION
Ecotoxicity:
No data available
Fish:
Crustacea: No data available
No data available
Algae:
Persistence / degradability: No data available
No data available
Bioaccumulative
potential(BCF):
Mobillity in soil
log Pow: No data available
No data available
Soil adsorption (Koc):
Henry's Law No data available
constant(PaM3/mol):

---

Section 13. DISPOSAL CONSIDERATIONS
Recycle to process, if possible. Consult your local regional authorities. You may be able to dissolve or mix material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber system.
Observe all federal, state and local regulations when disposing of the substance.

---

Section 14. TRANSPORT INFORMATION
Hazards Class: Does not correspond to the classification standard of the United Nations
Not Listed
UN-No:

---

Section 15. REGULATORY INFORMATION
Safe management ordinance of dangerous chemical product (State Council announces on January 26,
2002): Safe use and production, the storage of a dangerous chemical, transport, loading and unloading were
prescribed.
5-Bromo-2,3-pyridinediol

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  ——	5-bromo-3-(3-methoxy-propoxy)-1H-pyridin-2-one	865156-72-5	C9H12BrNO3	262.103

反应信息

• 作为反应物：
  描述：

  5-溴-2,3-二羟基吡啶 在 正丁基锂 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 2,3-二氢[1,4]二恶并[2,3-b]吡啶-7-甲醛
  参考文献：
  名称：

  Derivate des 1.3-Benzdioxols, 53 [1] Darstellung von N-Alkyl-2-aryl-pyrrolidinen

  摘要：

  摘要：使用内酯醚对1,3-苯并二氧杂环己烷基金属有机物、吡啶并[2.3-d]-1.3-二氧杂环己烷基金属有机物和吡啶并[2.3-b]-1.4-二氧杂环己烯基金属有机物进行转化并不成功。N-烷基-2-芳基吡咯烷10a-c、11a-c、12a、13a和14a通过醛4a-c经γ-酮腈7a-c和2-芳基-⊿1-吡咯烷8a-c合成；在某些情况下，收率很高。

  DOI：

  10.1515/znb-1984-1122
• 作为产物：
  描述：

  糠醛 在 溴 、 盐酸 、 氨基磺酸 作用下， 以 水 为溶剂， 以49.8 %的产率得到5-溴-2,3-二羟基吡啶
  参考文献：
  名称：

  稳定 MYC 启动子中的 G-四联体并抑制拓扑异构酶 I 的茚并异喹啉衍生物的药代动力学和抗癌活性的设计、合成和研究

  摘要：

  G-四链体是非规范的四链 DNA 二级结构。 MYC是主要癌基因， MYC启动子中形成的 G 四链体起到转录沉默子的作用，并且可以通过小分子稳定。我们之前揭示了茚并异喹啉抗癌药物的新作用机制，双重下调MYC和抑制拓扑异构酶I。在此，我们报告了基于所需取代基和π的新型7-氮杂-8,9-亚甲基二氧基茚并异喹啉的设计和合成。 –π 堆积相互作用。这些化合物可稳定MYC启动子 G-四链体，显着降低癌细胞中的 MYC 水平，并抑制拓扑异构酶 I。Raji 与 CA-46 细胞中的差异活性以及 MYC 依赖性细胞系中的细胞毒性证明了 MYC 靶向。研究了人类癌细胞系 NCI-60 组的细胞毒性。建立了良好的药代动力学，并在异种移植小鼠模型中证明了体内抗癌活性。此外，在原位胶质母细胞瘤小鼠模型中证明了良好的脑渗透性、脑药代动力学和抗癌活性。

  DOI：

  10.1021/acs.jmedchem.3c02303
• 作为试剂：
  描述：

  5-溴-2,3-二羟基吡啶 、 potassium carbonate 、 1,2-二溴乙烷 在 5-溴-2,3-二羟基吡啶 、 ice 、 乙酸乙酯 、 Sodium sulfate-III 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 7-溴-2,3-二氢-[1,4]二噁英[2,3-b]吡啶
  参考文献：
  名称：

  POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR

  摘要：

  本发明涉及用于治疗的化合物，包括含有该化合物的组合物，以及通过给予该化合物治疗疾病的方法。所提到的化合物是乙酰胆碱α7受体的正向变构调节剂（PAMs）。

  公开号：

  US20150231121A1

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005090304A1

  公开（公告）日：2005-09-29

  The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  这项发明涉及一般式(I)的新型氨基醇，其中X、R1、R2、R3、R4、R5和R6的定义详细描述在说明书中，以及它们的制备方法和将这些化合物用作药物，特别是作为肾素抑制剂。
• BROMODOMAIN INHIBITORS
  申请人：Quanticel Pharmaceuticals

  公开号：US20150111885A1

  公开（公告）日：2015-04-23

  The present invention relates to substituted heterocyclic derivative compounds, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Said compositions and methods are useful for the treatment of cancer and neoplastic disease.

  本发明涉及替代杂环衍生物化合物，包括所述化合物的组合物，以及通过抑制溴结构域介导的蛋白质乙酰赖氨酸区域的识别来进行表观遗传调控的所述化合物和组合物的用途。所述组合物和方法对于癌症和肿瘤性疾病的治疗是有用的。
• CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER
  申请人：Koura Minoru

  公开号：US20100280013A1

  公开（公告）日：2010-11-04

  [Object] It is to provide a novel LXRβ agonist useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C—R 7 ; each X and Y independently show CH 2 , C═O, SO 2 , etc; Z shows CH or N; each R 1 , R 2 and R 7 independently show a hydrogen atom, C 1-8 alkyl group, etc.; R 3 shows C 1-8 alkyl group; R 4 shows an optionally substituted C 6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group; R 5 and R 6 show a hydrogen atom, etc.; L shows a C 1-8 alkyl chain optionally substituted with an oxo group, etc.; and n shows any integer of 0 to 2.)

  它是提供一种新型的LXRβ激动剂，可用作预防和/或治疗动脉粥样硬化；动脉硬化，如由糖尿病引起的动脉硬化；血脂异常；高胆固醇血症；与脂质相关的疾病；由炎性细胞因子引起的炎症性疾病；过敏性皮肤病；糖尿病；或阿尔茨海默病的预防和/或治疗剂。【解决手段】由以下一般式（I）表示的羟甲基化合物或其盐，或它们的溶剂化合物： （其中，每个V和W独立地表示N或C—R 7 ；每个X和Y独立地表示CH 2 ，C═O，SO 2 等；Z表示CH或N；每个R 1 ，R 2 和R 7 独立地表示氢原子，C 1-8 烷基基团等；R 3 表示C 1-8 烷基基团；R 4 表示可选择地取代的C 6-10 芳基基团或可选择地取代的5-至11-成员杂环基团；R 5 和R 6 表示氢原子等；L表示可选择地取代有氧基团等的C 1-8 烷基链；n表示0至2的任意整数。】
• [EN] DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF<br/>[FR] DÉRIVÉS DE PIPERLONGUMINE ET LEURS UTILISATIONS
  申请人：AURANSA INC

  公开号：WO2019103897A1

  公开（公告）日：2019-05-31

  The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3- dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to processes for preparing the same; a pharmaceutical composition and formulation containing a derivative of piperlogumine; and use of the derivatives and analogs for treating cancer.

  本发明涉及一组1-[(E)-3-(3,4,5-三甲氧基苯基)丙-2-烯酰基]-2,3-二氢吡啶-6-酮（长椒碱）衍生物、类似物及其药学上可接受的盐。本发明还涉及制备这些衍生物的方法；含有长椒碱衍生物的药物组合物和配方；以及利用这些衍生物和类似物治疗癌症。
• DERIVATIVES OF PIPERLONGUMINE AND USES THEREOF
  申请人：Auransa Inc.

  公开号：US20200377510A1

  公开（公告）日：2020-12-03

  The present invention relates to a group of 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one (piperlongumine) derivatives, analogs and pharmaceutically acceptable salts thereof. The present invention also relates to a pharmaceutical composition and formulation containing a derivative of piperlongumine; and use of the derivatives and analogs for treating cancer, reducing inflammation and/or treating an autoimmune or inflammatory disease.

  本发明涉及一组1-[(E)-3-(3,4,5-三甲氧基苯基)丙-2-烯酰基]-2,3-二氢吡啶-6-酮（长椒碱）衍生物、类似物及其药学上可接受的盐。本发明还涉及含有长椒碱衍生物的药物组合物和配方；以及利用这些衍生物和类似物治疗癌症、减少炎症和/或治疗自身免疫或炎症性疾病。